Targeted Therapeutics Market Investment Opportunities, Industry Share & Trend Analysis Report to 2028
According to the most recent report by Emergen Research, the size of the global market for targeted therapeutics is anticipated to reach USD 162.89 billion and grow at a revenue CAGR of 7.1% during the forecast period. Rising rates of certain cancers can be linked to consistent market revenue growth. Different chemotherapy treatments are unable to distinguish between healthy and malignant cells, killing both types of cells. On the other hand, targeted therapies is a cancer treatment that uses medications to specifically target the proteins and genes that help cancer cells survive and develop.The tissue milieu that promotes the spread of cancer can be changed by using targeted therapies, or specific cancer-related cells such blood vessel cells can be targeted. Additionally, chemotherapy and other treatments are routinely combined with targeted medicines. Due to the rising incidence of different types of cancer, the US Food and Drug Administration has approved a number of targeted medicines over the years.
Age-related increases in cancer risk have been seen, with those 65 years of age or older accounting for about 60% of all cancer diagnoses. For the diagnosis and treatment of geriatric cancer patients, specialist techniques such targeted treatments are crucial given the rising frequency of cancer among an increasing senior population. Using targeted therapeutic therapy, numerous medically complex cases of metastatic renal cell carcinoma in geriatrics showed survival advantages.
Get PDF Sample Report + All Related Table and Graphs @ https://www.emergenresearch.com/request-sample/842
Some Key Highlights from the Report
Announcing a global partnership and licence agreement with Ionis Pharmaceuticals for tissue-targeted delivery of oligonucleotide therapeutics utilising Bicycles with high affinity to transferrin receptor, Bicycle Therapeutics PLC, a biotechnology company engaged in development of innovative and differentiated therapeutics class, made the announcement in July 2021. (TfR1).
Over the projected period, monoclonal antibodies are anticipated to have a particularly strong revenue share among the therapeutic segments. Cancer cells can be targeted and killed with precision using monoclonal antibodies that release cytotoxic chemicals. After binding to its target cell, an antibody produces a hazardous compound, such as a radioactive or poisonous chemical, which the target cell absorbs and finally suffocates. The absence of the antibody target prevents these poisons from affecting cells. Trastuzumab (for certain breast malignancies), alemtuzumab (for certain chronic leukemias), and cetuximab are examples of monoclonal antibodies (certain colorectal, head, lung, and neck cancers).
In the US, prostate cancer is the second leading cause of cancer-related death in men. Hormonal therapies are frequently added to the prostatectomy and radiation therapy currently being used to treat prostate cancer. Recurrence is also common in cases of prostate cancer, and many patients experience the development of metastatic prostate cancer, for which chemotherapy is only moderately successful and necessitates the use of targeted medicines following early therapies.
In 2020, the targeted therapeutics market in North America generated the highest revenue share, which can be attributable to the region’s rapid adoption of cutting-edge technologies, rising cancer incidence, and high healthcare spending. Furthermore, the presence of major industry players like Pfizer Inc. and Amgen Inc. is anticipated to support market expansion in this area.
Amgen Inc., Genentech Inc., Arcus Biosciences Inc., Gilead Sciences Inc., AstraZeneca PLC, Serina Therapeutics Inc., F. Hoffmann-La Roche & Co., Agenus Inc., Pfizer Inc., and Aurinia Pharmaceutical Inc. are a few of the significant businesses mentioned in the market study.
Emergen Research has segmented global targeted therapeutics market on the basis of therapy, disease indication, end-use, and region:
Therapy Outlook (Revenue, USD Billion; 2018–2028)
- Monoclonal Antibodies
- Small Molecule Inhibitors
Disease Indication Outlook (Revenue, USD Billion; 2018–2028)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Multiple Sclerosis
End-use Outlook (Revenue, USD Billion; 2018–2028)
- Cancer Treatment Centers
- Research Institutes
Regional Outlook (Revenue, USD Billion; 2018–2028)
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of MEA
For more Information or Any Query Visit @ https://www.emergenresearch.com/industry-report/targeted-therapeutics-market
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: [email protected]
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services